TNF and rheumatic disorder: Based on the review of the published cases of patients with rheumatic diseases treated with anti-TNF-α (n = 255), made by Ramos-Casals in 2010, it can be concluded that the risk of HBV reactivation is approximately 38 % (n = 87) in patients HBsAg (+), without preventive antiviral treatment [80].